22-26 June, 2022
ENYO Pharma will attend the EASL International Liver Congress at London in April 2022.
16-18 May, 2022
ENYO Pharma will attend the 22nd Bio€quity Europe, the Europe’s premier international showcase for financial dealmakers and biopharma executives to meet rising biotechs.
ENYO Pharma’s team will reconnect with investors and partners to accelerate the clinical development of its lead compound Vonafexor focused on kidney and liver diseases.
Jacky Vonderscher will also present “VONAFEXOR, a fibrolytic and anti-inflammatory for the treatment of kidney and liver diseases” in the Hot Topics Track #1 session,
23-25 March 2022
Jacky Vonderscher will attend the Tech Tour Future22 event, one of a series of EIC ScalingUp Roadshow events, and give a pitch about ENYO Pharma.
1,000 investors challenged over 1,000 selected tech entrepreneurs in 2021 over multiple sessions to level up their investment and growth. This event will allow us to meet the top only, to collaborate with Europe’s leading tech entrepreneurs and investors on future ambitions.
1-3 March, 2022
ENYO attended the 4th Chronic Kidney Disease Drug Development Summit, the only industry-led event dedicated to accelerating the frontier of preventative and regenerative therapies to meaningfully target kidney disease and enlighten opportunities for indication expansion into rare renal disorders. We presented a poster entitled “VONAFEXOR induces renal and hepatic improvements in NASH-LIVIFY trial results”.
28 Feb-4 March 2022
Jacky Vonderscher presented ENYO Pharma and gave a pitch in the “Biotech, Pharma, Therapeutics” session in front of strategic investors & partners among the top 50 European deep tech growth companies funded by EIC.